In light of this, a Phase II clinical trial was conducted in 2010 to evaluate the efficacy of loading autologous DCs with WT1 antigen via mRNA electroporation as an adjunctive treatment strategy for AML patients who had completed chemotherapy (NCT00965224). Here, WT1 is linked to acute myeloid leukemia.